|Targets||Sphingosine 1 Phosphate Receptor|
|Description||This active molecular is a S1P1/S1P5 agonist with limited activity at S1P3. AMG 369 has no activity at S1P2 and S1P4. AMG-369 is shown to reduce blood lymphocyte counts 24 hours postdose with dosed orally at 0.1 mg/kg. Till Jun 2016, no recent reports of development identified for preclinical development in Multiple-sclerosis in USA were published yet.|
|Synonyms||AMG-369; AMG 369; AMG369; KB-74649; KB74649; KB 74649. 1-[[3-fluoro-4-[6-(1-phenylcyclopropyl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]phenyl]methyl]azetidine-3-carboxylicacid; ZINC216149127;1202073-26-4|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
CYM 50260 has been found to be a S1P4 agonist.
CYM 50308 has been found to be an effective and selective S1P4 agonist.
The hydrochloride salt form of CYM 50358, which has been found to be an effective S1P4 antagonist.
Ozanimod, also known as RPC1063, is a selective oral S1P Receptor 1 modulator.
This active molecular is a S1P1/S1P5 agonist with limited activity at S1P3. AMG 369 has no activity at S1P2 and S1P4. AMG-369 is shown to reduce blood lymphocyt...
JTE 013 has been found to be an antagonist of Sphingosine-1-Phosphate Receptor-2 (S1P2R).
CS-0777 is a selective sphingosine 1-phosphate receptor modulator agonist. It is in clinical trials for the treatment of multiple sclerosis, but no recent devel...
The hydrochloride salt form of PF-543, a novel SphK1 inhibitor that could exhibit activity in induceing necrosis in human colorectal cancer cells in biological ...